"Art Therapy" in Acute Psychiatry

NCT03575442 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-10-10

No results posted yet for this study

Summary

Background: Given the complexity of this problem, psychiatric in-patients in the acute stage of their disease need different types of therapeutic programs to recover they mental health state. Usually they're submitted to systematic biological programs (namely psychopharmaceuticals), often considered a priority when compared to psychosocial programs. Among the different therapies that have been introduced in this context "art therapy", also named creative therapy, can constitute a treatment that complements the allopathic treatments, providing improvements in self-esteem and self-efficiency, distraction and relief from concerns and negative thoughts. Scientific evidence on the effects of psychosocial programs in the context of hospitalization of acute cases is scarce.

Aims: a) evaluate the effectiveness of a 3 session program of "art therapy" in changing emotional indicators, namely depression, anxiety, stress, and psychological well-being, in individuals with mental illness; b) analyze the meanings a person attributes to his creative self-expression.

Method: This is a pre-experimental, prospective study, with a pre test-post test design without control group, with a mixed approach (quantitative and qualitative). The study was performed in the psychiatry unit (Psiquiatria B), in the Centro Hospitalar e Universitário de Coimbra - Portugal. The target population was composed by men (older than 18), hospitalized in this ward. The exclusion criteria were: individuals with active psychotic symptomology, in manic phase and/or refusing to participate. The instruments used to collect information were: Depression, Anxiety and Stress Scale \[DASS-21\]; Ryff Scales of Psychological Well-Being (SPWB - 18 item version) and a semi-structured interview.

Data collection and the development of this study occurred in the following manner:

* Initial evaluation to verify the sample selection criteria in the first 48 hours after patient hospitalization;
* Obtain informed consent for the application of instruments and participation in the "art therapy" intervention program;
* Application of instruments (DASS-21 and SPWB-18 item version) before intervention;
* Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
* In the end of the program, the same instruments were reapplied.

Conditions

  • Schizophrenia
  • Mood Disorders
  • Mental Disorder
  • Nurse-Patient Relations

Interventions

BEHAVIORAL

3 session program of "art therapy"

With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.

Sponsors & Collaborators

  • Unidade Local de Saúde de Coimbra, EPE

    lead OTHER

Principal Investigators

  • Clara A. Campos, RN · Unidade Local de Saúde de Coimbra, EPE

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2018-03-01
Completion
2020-12-31

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03575442 on ClinicalTrials.gov